Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.
Authors
Byrne, A TO'Connor, A E
Hall, M
Murtagh, J
O'Neill, K
Curran, K M
Mongrain, K
Rousseau, J A
Lecomte, R
McGee, S
Callanan, J J
O'Shea, D F
Gallagher, W M
Affiliation
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.Issue Date
2009-11-03MeSH
AnimalsCell Line, Tumor
Cells, Cultured
Endothelial Cells
Female
Humans
Magnetic Resonance Imaging
Mammary Neoplasms, Experimental
Mice
Mice, Inbred C57BL
Photochemotherapy
Photosensitizing Agents
Positron-Emission Tomography
Pyrroles
Tissue Distribution
Metadata
Show full item recordCitation
Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. 2009, 101 (9):1565-73 Br. J. CancerJournal
British journal of cancerDOI
10.1038/sj.bjc.6605247PubMed ID
19826417Abstract
Photodynamic therapy (PDT) is a treatment modality for a range of diseases including cancer. The BF(2)-chelated tetraaryl-azadipyrromethenes (ADPMs) are an emerging class of non-porphyrin PDT agent, which have previously shown excellent photochemical and photophysical properties for therapeutic application. Herein, in vivo efficacy and mechanism of action studies have been completed for the lead agent, ADMP06.A multi-modality imaging approach was employed to assess efficacy of treatment, as well as probe the mechanism of action of ADPM06-mediated PDT.
Tumour ablation in 71% of animals bearing mammary tumours was achieved after delivery of 2 mg kg(-1) of ADPM06 followed immediately by light irradiation with 150 J cm(-2). The inherent fluorescence of ADPM06 was utilised to monitor organ biodistribution patterns, with fluorescence reaching baseline levels in all organs within 24 h. Mechanism of action studies were carried out using dynamic positron emission tomography and magnetic resonance imaging techniques, which, when taken together, indicated a decrease in tumour vascular perfusion and concomitant reduction in tumour metabolism over time after treatment.
The encouraging treatment responses in vivo and vascular-targeting mechanism of action continue to indicate therapeutic benefit for this new class of photosensitiser.
Item Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6605247
Scopus Count
Collections
Related articles
- Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo.
- Authors: O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM
- Issue date: 2012 Feb 1
- Automated radiosynthesis and in vivo evaluation of (18)F-labeled analog of the photosensitizer ADPM06 for planning photodynamic therapy.
- Authors: Kawamura K, Yamasaki T, Fujinaga M, Kokufuta T, Zhang Y, Mori W, Kurihara Y, Ogawa M, Tsukagoe K, Nengaki N, Zhang MR
- Issue date: 2023 Jul 17
- The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents.
- Authors: Mukai H, Wada Y, Watanabe Y
- Issue date: 2013 Aug
- Fluorescence and photodynamic effects of bacteriochlorin a observed in vivo in 'sandwich' observation chambers.
- Authors: van Leengoed HL, Schuitmaker JJ, van der Veen N, Dubbelman TM, Star WM
- Issue date: 1993 May
- A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia.
- Authors: Gallagher WM, Allen LT, O'Shea C, Kenna T, Hall M, Gorman A, Killoran J, O'Shea DF
- Issue date: 2005 May 9